+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PTC Therapeutics - logo

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

From
Neuromuscular Disease Therapeutics Market 2025-2029 - Product Thumbnail Image

Neuromuscular Disease Therapeutics Market 2025-2029

  • Report
  • December 2024
  • 195 Pages
  • Global
From
Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2024-2028 - Product Thumbnail Image

Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2024-2028

  • Report
  • September 2024
  • 167 Pages
  • Global
From
From
From
From
Duchenne Muscular Dystrophy Market Report 2025 - Product Thumbnail Image

Duchenne Muscular Dystrophy Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
From
Transthyretin Amyloidosis Treatment Market Report 2025 - Product Thumbnail Image

Transthyretin Amyloidosis Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Friedreich Ataxia - Global Clinical Trials Review, 2025 - Product Thumbnail Image

Friedreich Ataxia - Global Clinical Trials Review, 2025

  • Clinical Trials
  • January 2025
  • 108 Pages
  • Global
From
From
Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2024

  • Clinical Trials
  • January 2024
  • 257 Pages
  • Global
From
Loading Indicator